Synergistic antitumor efficacy against the EGFRvIII+HER2+ breast cancers by combining trastuzumab with anti-EGFRvIII antibody CH12-Reference-Cited by-同舟云学术

Synergistic antitumor efficacy against the EGFRvIII+HER2+ breast cancers by combining trastuzumab with anti-EGFRvIII antibody CH12

Published:2015-10-14 Issue:36 Volume:6 Page:38840-38853
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Xu Wen¹²,Bi Yanyu²,Zhang Jiqin²,Kong Juan²,Jiang Hua²,Tian Mi²,Li Kesang²,Wang Biao²,Chen Cheng²,Song Fei²,Pan Xiaorong²,Shi Bizhi²,Kong Xianming²,Gu Jianren²,Cai Xiumei¹,Li Zonghai²

Affiliation:

1. Medical School of Fudan University, Shanghai, China

2. State Key Laboratory of Oncogenes & Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. TSR-033, a Novel Therapeutic Antibody Targeting LAG-3, Enhances T-Cell Function and the Activity of PD-1 Blockade In Vitro and In Vivo;Molecular Cancer Therapeutics;2018-12-26

2. Recent Insights into the Development of Preclinical Trastuzumab- Resistant HER2+ Breast Cancer Models;Current Medicinal Chemistry;2018-05-22

3. The Effect of and Mechanism Underlying Autophagy in Hepatocellular Carcinoma Induced by CH12, a Monoclonal Antibody Directed Against Epidermal Growth Factor Receptor Variant III;Cellular Physiology and Biochemistry;2018

4. The EGFR variant III mutant as a target for immunotherapy of glioblastoma multiforme;European Journal of Pharmacology;2017-09

5. A brief perspective of drug resistance toward EGFR inhibitors: the crystal structures of EGFRs and their variants;Future Medicinal Chemistry;2017-05